Experience with a Novel Efalizumab‐Based Immunosuppressive Regimen to Facilitate Single Donor Islet Cell Transplantation
Nicole A. Turgeon(Emory University), Christian P. Larsen(Emory University Hospital), Thomas C. Pearson(Emory Healthcare), Marti H. Sears(Emory University), Allan D. Kirk(University of Calgary), Andrew Adams(University of Minnesota), Andrew J. Page(Emory University), Jose A. Cano(Emory University), José G. Ávila(Emory University), I.R. Badell(Emory University), P.H Bowen(Emory University), JA Hutchinson(Emory University)
Cited by 106
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566